Loading...
XKRX
003120
Market cap96mUSD
Jul 10, Last price  
20,200.00KRW
1D
1.56%
1Q
-11.98%
Jan 2017
-17.89%
Name

Ilsung Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:003120 chart
P/E
124.09
P/S
2.25
EPS
162.78
Div Yield, %
4.95%
Shrs. gr., 5y
11.64%
Rev. gr., 5y
9.63%
Revenues
64.29b
-6.85%
78,833,528,00079,870,404,00071,467,214,00068,594,693,00068,191,775,02077,160,760,62062,807,489,69062,828,920,56061,745,116,14067,463,384,16067,043,035,12061,652,595,25048,411,627,88040,600,732,00042,089,835,82061,247,847,00078,053,232,00069,018,341,00064,291,703,000
Net income
1.17b
-91.10%
17,699,848,00034,163,059,0008,049,787,0006,297,465,00035,083,007,47036,451,736,0807,955,018,2804,034,563,91098,853,930,9303,017,242,0402,628,652,9302,945,528,7406,718,550,3603,220,257,000-1,367,510,420108,669,346,000-20,940,893,00013,094,107,0001,165,835,000
CFO
17.28b
P
4,171,398,00016,535,708,0001,265,121,00018,644,306,0008,244,202,610-11,318,601,8705,063,947,6204,190,571,1006,041,134,630-31,013,469,62010,158,675,33015,091,217,1604,388,672,7101,557,299,0005,704,073,470-38,966,011,000-41,474,993,000-4,255,830,00017,278,670,000
Dividend
Dec 29, 20251000 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Founded in 1954, Ilsung Pharmaceuticals Co., Ltd. operates as a key pharmaceutical firm in South Korea, headquartered in Seoul. The company specializes in the development and distribution of a comprehensive range of medicinal products. Its extensive portfolio includes antibacterial agents, pain management drugs, muscle relaxants, anticoagulants, various cardiovascular and circulatory system treatments, diagnostic contrast agents, diabetes therapies, gastrointestinal medicines, antiviral compounds, anti-emetic medications, respiratory care solutions, anesthetics, and antipyretics.
URL
https://www.ilsung-ph.co.kr
IPO date
Jan 14, 1985
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT